BG
GBIO

Bellevue Group’s Generation Bio GBIO Stock Holding History

Bellevue Group’s Portfolio GBIO Stock Details GBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-391,886
Closed -$9.68M – 166
2024
Q3 		$9.68M Hold
391,886
– – 0.16% 84
2024
Q2 		$11.1M Buy
391,886
+5,728
+1% +$186K 0.18% 86
2024
Q1 		$15.7M Buy
386,158
+24,450
+7% +$576K 0.24% 84
2023
Q4 		$5.97M Hold
361,708
– – 0.09% 92
2023
Q3 		$13.7M Sell
361,708
-320
-0.1% -$15.2K 0.22% 82
2023
Q2 		$19.9M Hold
362,028
– – 0.28% 77
2023
Q1 		$15.6M Sell
362,028
-700
-0.2% -$33.9K 0.23% 86
2022
Q4 		$14.3M Hold
362,728
– – 0.19% 93
2022
Q3 		$19.3M Hold
362,728
– – 0.28% 83
2022
Q2 		$23.8M Sell
362,728
-5,490
-1% -$359K 0.34% 79
2022
Q1 		$27M Sell
368,218
-19,000
-5% -$1.1M 0.31% 86
2021
Q4 		$27.4M Buy
387,218
+140,000
+57% +$24.4M 0.28% 92
2021
Q3 		$62M Sell
247,218
-600
-0.2% -$144K 0.63% 53
2021
Q2 		$66.7M Buy
247,818
+8,500
+4% +$2.54M 0.65% 52
2021
Q1 		$68.1M Buy
239,318
+6,000
+3% +$1.92M 0.72% 47
2020
Q4 		$66.1M Buy
233,318
+45,318
+24% +$14.5M 0.76% 38
2020
Q3 		$58.1M Buy
188,000
+44,000
+31% +$10.5M 0.8% 37
2020
Q2 		$30.2M Buy
+144,000
New +$32.1M 0.43% 58

Other funds holding GBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bellevue Group's GBIO Position: Q4 2024 in Review

Bellevue Group sold out of Generation Bio (GBIO) in Q4 2024, closing a stake of 391,886 shares — an estimated $9.68M sold.

Bellevue Group first reported a position in GBIO in Q2 2020 and held it in 18 quarters. The position peaked at $68.1M in Q1 2021. 78 funds tracked by Wall St. Rank hold GBIO as of Q4 2024.

  • Bellevue Group reported no remaining Generation Bio position as of Q4 2024 after selling out during the quarter.
  • Bellevue Group sold 391,886 Generation Bio shares in Q4 2024, an estimated $9.68M.
  • Bellevue Group first reported a position in Generation Bio in Q2 2020 and held it in 18 quarters.
  • Bellevue Group's Generation Bio position peaked at $68.1M in Q1 2021.
  • 78 funds tracked by Wall St. Rank held Generation Bio as of Q4 2024.

Based on Bellevue Group's 13F filing for Q4 2024, filed 14 Feb 2025.